[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639608":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":19,"responsibleParty":26,"collaborators":19,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":34,"eligibilityCriteria":35,"healthyVolunteers":30,"sex":36,"minAge":37,"maxAge":19,"enrollmentInfo":38,"targetDuration":19,"studyType":41,"phases":42,"briefSummary":44,"conditions":45,"keywords":19,"overallStatus":47,"whyStopped":19,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":19},{"fullName":5,"class":6},"argenx","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Empasiprubart IV","EXPERIMENTAL","Participants receive empasiprubart IV",[13],"Biological: Empasiprubart IV",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Intravenous infusions of empasiprubart",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Sabine Coppieters, MD","CONTACT","857-350-4834","clinicaltrials@argenx.com",{"type":27,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100639608","phase-1-a-study-to-assess-the-effect-of-empasiprubart-on-nerve-morphology-by-ultrasound-in-adults-with-multifocal-motor-neuropathy-100639608",false,"NCT07610564","A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy","An Open-Label, Single-Arm, Phase 1b Study to Evaluate the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy","EmpaSound","Inclusion Criteria:\n\n* Is at least 18 years old\n* Diagnosed with MMN\n* Has an MMN-RODS centile score of ≤90\n* Has confirmed nerve thickening in at least 1 nerve per ultrasound measurement\n\nExclusion Criteria:\n\n* Besides the indication under study, known autoimmune disease or any medical condition that, in the investigator's opinion, would interfere with an accurate assessment of clinical symptoms of MMN or puts the participant at undue risk.","ALL","18 Years",{"count":39,"type":40},60,"ESTIMATED","INTERVENTIONAL",[43],"PHASE1","The main purpose of the study is to evaluate empasiprubart use in adults living with Multifocal Motor Neuropathy (MMN). The researchers will evaluate the effect of empasiprubart on the thickness of the nerves, muscle strength, movement, and on the potential improvement of grip strength of the participants in handling objects.\n\nThe study consists of an open-label treatment period where all participants will receive empasiprubart intravenously (IV). After the last dose of empasiprubart participants will enter a safety follow-up period for up to 15 months.\n\nThe total study duration for each participant will be approximately 29 months.\n\nMore information can be found here: clinicaltrials.argenx.com\u002Fempasound",[46],"Multifocal Motor Neuropathy (MMN)","NOT_YET_RECRUITING","2026-05-20",{"date":50,"type":51},"2026-05-28","ACTUAL",{"date":53,"type":40},"2026-06-30",{"date":55,"type":40},"2030-04-01",{"name":5,"class":6}]